Imsamotide/Etimumotide

依沙莫肽/艾替莫肽

Report date: 2026/04/28 20:00:22

Base Information

Drug NameImsamotide/Etimumotide
Drug Alias NamePD-L1/IDO peptide vaccine (IO Biotech)IDO-derived peptide vaccine+PD-L1-derived peptide vaccine (IO Biotech)IDO-derived peptide vaccine/PD-L1-derived peptide vaccine (IO Biotech)Imsapepimut/EtimupepimutCylembio +[8] 
ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Synthetic peptide vaccineVaccines > Vaccine type > Combination vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsSolid tumoursUrinary Bladder NeoplasmsCarcinoma, Non-Small-Cell Lung +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumUnited States +[15] 
CombinationsYes ImsamotideEtimumotide
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesIo Biotech Inc
China Registration ClassN/A

Develop Information

Active CompaniesIo Biotech IncThe University Of California DavisIo Biotech Aps
Inactive CompaniesN/A
Active IndicationsSolid tumoursUrinary Bladder NeoplasmsCarcinoma, Non-Small-Cell Lung +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A